Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer

Neoplasia

Volumn 2, Issue 1-2, 2000, Pages 166-189

  Kurhanewicz, John ^a,b   Vigneron, Daniel B ^a   Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Magnetic resonance imaging (MRI); Magnetic resonance spectroscopic imaging (MRSI); Metabolism; Morphology; Prostate and brain cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE; CITRIC ACID; FLUORODEOXYGLUCOSE; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; PHOSPHORUS 31; PROSTATE SPECIFIC ANTIGEN;

BRAIN CANCER; DIAGNOSTIC ACCURACY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034087595     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900081     Document Type: Review

References (200)

1. Arnold DL, Shoubridge EA, Feindel W, and Villemure JG (1987). Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy. Can J Neurol Sci 14, 570-575.
2. Arnold DL, Shoubridge EA, Emrich J, Feindel W, and Villemure JG (1989). Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. Invest Radiol 24, 958-961.
3. Arnold DL, Shoubridge EA, Villemure JG, and Feindel W (1990). Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed 3, 184-189.
4. Arnold DL, Emrich JF, Shoubridge EA, Villemure JG, and Feindel W (1991). Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. J Neurosurg 74, 447-453.
5. Arnold DL, and De Stefano N (1997). Magnetic resonance spectroscopy in vivo: applications in neurological disorders. Ital J Neurol Sci 18, 321-329.
6. Barker PB, Glickson JD, and Bryan RN (1993). In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 5, 32-45.
7. Bottomley PA, Charles HC, Roemer PB, Flamig D, Engeseth H, Edelstein WA, and Mueller OM (1988). Human In Vivo Phosphate Metabolite Imaging with 31P NMR. Magn Reson Med 7, 319-336.
8. Coutts GA, Bryant DJ, Collins AG, Cox IJ, Sargentoni J, and Gadian DG (1989). 31P magnetic resonance spectroscopy of the normal human brain: approaches using four dimensional chemical shift imaging and phase mapping techniques. NMR Biomed 1, 190-197.
9. den HJ, Luyten PR, Marien AJ, Segebarth CM, Baleriaux DF, de BR, and van OD (1989). Potentials of quantitative image-localized human 31P nuclear magnetic resonance spectroscopy in the clinical evaluation of intracranial tumors. Magn Reson Q 5, 152-168.
10. Hubesch B, Sappey MD, Roth K, Meyerhoff DJ, Matson GB, and Weiner MW (1990). P-31 MR spectroscopy of normal human brain and brain tumors. Radiology 174, 401-409.
11. Kurhanewicz J, Dahiya R, Macdonald JM, Jajodia P, Chang LH, James TL, and Narayan P (1992). Phosphorus metabolite characterization of human prostatic adenocarcinoma in a nude mouse model by 31P magnetic resonance spectroscopy and high pressure liquid chromatography. NMR Biomed 5, 185-192.
12. Maudsley AA, Hilal SK, Simon HE, and Wittekoek S (1984). In vivo MR spectroscopic imaging with P-31. Work in progress. Radiology 153, 745-750.
13. Narayan P, Jajodia P, Kurhanewicz J, Thomas A, MacDonald J, Hubesch B, Hedgcock M, Anderson CM, James TL, and Tanagho EA (1991). Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31-phosphorus magnetic resonance spectroscopy: a preliminary report. J Urol 146, 66-74.
14. Narayan P, and Kurhanewicz J (1992). Magnetic resonance spectroscopy in prostate disease: diagnostic possibilities and future developments. Prostate Suppl 4, 43-50.
15. Segebarth CM, Baleriaux DF, Arnold DL, Luyten PR, and Den HJ (1987). MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment. Radiology 165, 215-219.
16. Segebarth CM, Baleriaux DF, de BR, van OD, Marien A, Luyten PR, and Den HJ (1989). 1H image-guided localized 31P MR spectroscopy of human brain: quantitative analysis of 31P MR spectra measured on volunteers and on intracranial tumor patients. Magn Reson Med 11, 349-366.
17. Sutton LN, Lenkinski RE, Cohen BH, Packer RJ, and Zimmerman RA (1990). Localized 31P magnetic resonance spectroscopy of large pediatric brain tumors. J Neurosurg 72, 65-70.
18. Thomas MA, Kurhanewicz J, Jajodia P, James TL, Narayan P, and Weiner MW (1990). Transrectal Localized 31-Phosphorus MR Spectroscopy of Human Prostate In Vivo. Presented at SMRM Ninth Annual Scientific Meeting. New York, NY, USA. pp. 2, 965.
19. Vigneron DB, Nelson SJ, Murphy BJ, Kelley DA, Kessler HB, Brown TR, and Taylor JS (1990). Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. Radiology 177, 643-649.
20. 1H Spectroscopy of the Human Prostate In Vivo. Presented at SMRM Ninth Annual Scientific Meeting. New York, NY, USA. pp. 1, 288.
21. Schiebler ML, Schnall MD, Pollack HM, Lenkinski RE, Tomaszewski JE, Wein AJ, Whittington R, Rauschning W, and Kressel HY (1993). Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 189, 339-352.
22. Kamada K, Houkin K, Hida K, Matsuzawa H, Iwasaki Y, Abe H, and Nakada T (1994). Localized proton spectroscopy of focal brain pathology in humans: significant effects of edema on spin-spin relaxation time. Magn Reson Med 31, 537-540.
23. Luyten PR, Marien AJ, and Den HJ (1991). Acquisition and quantitation in proton spectroscopy. NMR Biomed 4, 64-69.
24. Langkowski JH, Wieland J, Bomsdorf H, Leibfritz D, Westphal M, Offermann W, and Maas R (1989). Pre-operative localized in vivo proton spectroscopy in cerebral tumors at 4.0 Tesla - first results. Magn Reson Imaging 7, 547-555.
25. Saikawa S, Suzuki Y, Tomoi M, Yoshida M, Ishii Y, and Okada K (1995). Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy. Nippon Hinyokika Gakkai Zasshi 86, 1673-1680.
26. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, and Narayan P (1995). Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 45, 459-466.
27. Brown TR (1992). Practical applications of chemical shift imaging. NMR Biomed 5, 238-243.
28. Brown TR, Kincaid BM, and Ugurbil K (1982). NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA 79, 3523-3526.
29. Spielman D, Webb P, and Macocski A (1989). A statistical framework for in vivo spectroscopic imaging. J Magn Reson 79, 66-77.
30. Derby K, Hawryszko C, and Tropp J (1989). Baseline deconvolution, phase correction, and signal quantification in Fourier localized spectroscopic imaging. Magn Reson Med 12, 235-240.
31. Adalsteinsson E, Irarrazabal P, Spielman DM, and Macovski A (1995). Three-dimensional spectroscopic imaging with time-varying gradients. Magn Reson Med 33, 461-466.
32. Duijn JH, Matson GB, Maudsley AA, and Weiner MW (1992). 3D phase encoding 1H spectroscopic imaging of human brain. Magn Reson Imaging 10, 315-319.
33. Posse S, Tedeschi G, Risinger R, Ogg R, and Le BD (1995). High speed 1H spectroscopic imaging in human brain by echo planar spatial-spectral encoding. Magn Reson Med 33, 34-40.
34. Posse S, Schuknecht B, Smith ME, van ZP, Herschkowitz N, and Moonen CT (1993). Short echo time proton MR spectroscopic imaging. J Comput Assist Tomogr 17, 1-14.
35. Posse S, DeCarli C, and Le BD (1994). Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology 192, 733-738.
36. 3) spatial resolution. Radiology 198, 795-805.
37. Vigneron D, Nelson S, and Kurhanewicz J (1996). Proton Chemical Shift Imaging of Cancer. In Magnetic Resonance Imaging of the Body, Chap. 12. Hricak, Higgins and Helms (Eds). Raven Press, New York, NY. pp. 205-220.
38. Roos MS, Wong STS, and Frederick Bd (1990). Fast Spectroscopic Imaging with Oscillating Gradients and Stochastic Excitation. Book of Abstracts, 9th Annual Meeting of the Society of Magnetic Resonance in Medicine. p. 135 (abstract).
39. Duyn JH, Gillen J, Sobering G, van Zijl PC, and Moonen CT (1993). Multisection proton MR spectroscopic imaging of the brain. Radiology 188, 277-282.
40. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, Frank JA, Dwyer AJ, Alger JR, and Di CG (1992). Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 185, 675-686.
41. Luyten PR, Marien AJ, Heindel W, van GP, Herholz K, den HJ, Friedmann G, and Heiss WD (1990). Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 176, 791-799.
42. van ZP, Moonen CT, Gillen J, Daly PF, Miketic LS, Frank JA, DeLaney TF, Kaplan O, and Cohen JS (1990). Proton magnetic resonance spectroscopy of small regions (1 ml) localized inside superficial human tumors. A clinical feasibility study. NMR Biomed 3, 227-232.
43. Nelson SJ, Vigneron DB, Star-Lack J, and Kurhanewicz J (1997). High spatial resolution and speed in MRSI. NMR Biomed 10, 411-422.
44. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, and Sauter R (1989). Localized high-resolution proton NMR spectroscopy using echoes: initial applications to human brain in vivo. Magn Reson Med 9, 79-93.
45. Moonen CT, von KM, van ZP, Cohen J, Gillen J, Daly P, and Wolf G (1989). Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy. NMR Biomed 2, 201-208.
46. Bottomley PA (1987). Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508, 333-348.
47. Star LJ, Nelson SJ, Kurhanewicz J, Huang LR, and Vigneron DB (1997). Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 38, 311-321.
48. Star LJ, Vigneron DB, Pauly J, Kurhanewicz J, and Nelson SJ (1997). Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging 7, 745-757.
49. Bracewell RN (1978). The Fourier Transfrom and its Applications. McGraw-Hill, New York. pp. 104-107.
50. Marcei TH, and Booker HR (1984). High-resolution magnetic resonance spectra from sensitive region defined with pulsed field gradients. J Magn Reson 57, 157-163.
51. Pauly J, Le Roux P, Nishimura D, and Macovski A (1991). Parameter relations for the Shinnar-Le Roux selective excitation pulse design algorithm. IEEE Trans Med Imaging 10, 53-65.
52. Shachar-Hill Y, Pfeffer PE, and Germann MW (1996). Following plant metabolism in vivo and in extracts with heteronuclear two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 243, 110-118.
53. Shungu DC, and Glickson JD (1994). Band-selective spin echoes for in vivo localized 1H NMR spectroscopy. Magn Reson Med 32, 277-284.
54. Singh S, Rutt BK, and Henkelman RM (1990). Projection presaturation: a fast and accurate technique for multidimensional spatial localization. J Magn Reson 87, 567-583.
55. Singh S, Rutt BK, and Napel S (1990). Projection presaturation II. Single-shot localization of multiple regions of interest. J Magn Reson 90, 313-329.
56. Le Roux P, Gilles RJ, McKinnon GC, and Carlier PG (1998). Optimized outer volume suppression for single-shot fast spin-echo cardiac imaging. J Magn Reson Imaging 8, 1022-1032.
57. Males RG, Vigneron DB, Star-Lack J, Falbo SC, Nelson SJ, Hricak H, and Kurhanewicz J (2000). Clinical Application of BASING and Spectral/Spatial Water and Lipid Suppression Pulses for Prostate Cancer Staging and Localization by In Vivo 3D 1H Magnetic Resonance Spectroscopic Imaging. Magnetic Resonance In Medicine 43, 17-22.
58. Tran T-KC, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson SJ, and Hurd R (2000). Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med In Med 2000, 23-33.
59. Tran T-KC, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson SJ, and Hurd RJ (1999). Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine, Philadelphia, PA 1, 248.
60. Haase A, Frahm J, Hanicke W, and Matthaei D (1985). 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 30, 341-344.
61. Bydder GM, and Young IR (1985). MR imaging: clinical use of the inversion recovery sequence. J Comput Assist Tomogr 9, 659-675.
62. Tran T-KC, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson SJ, and Hurd R (2000). Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med In Med 2000, 23-33.
63. Spielman DM, Pauly JM, Macovski A, Glover GH, and Enzmann DR (1992). Lipid-suppressed single-and multisection proton spectroscopic imaging of the human brain. J Magn Reson Imaging 2, 253-262.
64. Duyn JH, Frank JA, and Moonen CT (1995). Incorporation of lactate measurement in multi-spin-echo proton spectroscopic imaging. Magn Reson Med 33, 101-107.
65. Wald LL, Moyher SE, Day MR, Nelson SJ, and Vigneron DB (1995). Proton spectroscopic imaging of the human brain using phased array detectors. Magn Reson Med 34, 440-445.
66. Wald LL, Carvajal L, Moyher SE, Nelson SJ, Grant PE, Barkovich AJ, and Vigneron DB (1995). Phased array detectors and an automated intensity-correction algorithm for high-resolution MR imaging of the human brain. Magn Reson Med 34, 433-439.
67. Moyher SE, Vigneron DB, and Nelson SJ (1995). Surface coil MR imaging of the human brain with an analytic reception profile correction. J Magn Reson Imaging 5, 139-144.
68. Gruetter R, Weisdorf SA, Rajanayagan V, Terpstra M, Merkle H, Truwit CL, Garwood M, Nyberg SL, and Uagurbil K (1998). Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson 135, 260-264.
69. Hetherington HP, Pan JW, Chu WJ, Mason GF, and Newcomer BR (1997). Biological and clinical MRS at ultra-high field. NMR Biomed 10, 360-371.
70. Pan JW, Twieg DB, and Hetherington HP (1998). Quantitative spectroscopic imaging of the human brain. Magn Reson Med 40, 363-369.
71. Nelson SJ, and Brown TR (1987). A new method for automatic quantification of 1-D spectra with low signal to noise ratio. J Magn Reson 75, 229-243.
72. Nelson S, and Brown T (1989). A study of the accuracy of quantification which can be obtained from 1-D NMR spectra using the PIQABLE algorithm. J Magn Reson 84, 95-109.
73. van der Veen JW de Beer R, Luyten PR, and van Ormondt D (1988). Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 6, 92-98.
74. Tropp JS, Sugiura S, Derby KA, Suzuki Y, Hawryszko C, Yamagata H, Klein JE, Ortendahl DA, Kaufman L, and Acosta GF (1988). Characterization of MR spectroscopic imaging of the human head and limb at 2.0 T. Radiology 169, 207-212.
75. Twieg DB, Meyerhoff DJ, Hubesch B, Roth K, Sappey MD, Boska MD, Gober JR, Schaefer S, and Weiner MW (1989). Phosphorus-31 magnetic resonance spectroscopy in humans by spectroscopic imaging: localized spectroscopy and metabolite imaging. Magn Reson Med 12, 291-305.
76. Lenkinski RE, Holland GA, Allman T, Vogele K, Kressel HY, Grossman RI, Charles HC, Engeseth HR, Flamig D, and MacFall JR (1988). Integrated MR imaging and spectroscopy with chemical shift imaging of P-31 at 1.5 T: initial clinical experience. Radiology 169, 201-206.
77. Nelson SJ, Vigneron DB, and Dillon WP (1999). Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 12, 123-138.
78. Simmons ML, Frondoza CG, and Coyle JT (1991). Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 37-45.
79. Negendank WG, Sauter R, BrownTR, et al. (1996). Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 84, 449-458.
80. Rutter A, Hugenholtz H, Saunders JK, and Smith IC (1995). Classification of brain tumors by ex vivo 1H NMR spectroscopy. J Neurochem 64, 1655-1661.
81. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, and Arnold DL (1996). Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 2, 323-325.
82. Somorjai RL, Dolenko B, Nikulin AK, et al. (1996). Classification of 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. J Magn Reson Imaging 6, 437-444.
83. Krouwer HG, Kim TA, Rand SD, et al. (1998). Single-voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm. AJNR Am J Neuroradiol 19, 1695-1703.
84. Rand SD, Prost R, Haughton V, Mark L, Strainer J, Johansen J, Kim TA, Chetty VK, Mueller W, Meyer G, and Krouwer H (1997). Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 18, 1695-1704.
85. Rand SD (1999). Medical College of Wisconsin. Personal communication.
86. Kinoshita Y, Kajiwara H, Yokota A, and Koga Y (1993). Proton magnetic resonance spectroscopy of astrocytic tumors: an in vitro study. Neurol Med Chir (Tokyo) 33, 350-359.
87. Cheng LL, Chang IW, Louis DN, and Gonzalez RG (1998). Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 58, 1825-1832.
88. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, and Gonzalez RG (1997). Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94, 1608-1643.
89. Barton SJ, Howe FA, Tomlins AM, Cudlip SA, Nicholson JK, Bell BA, and Griffiths JR (1999). Comparison of in vivo 1H MRS of human brain tumours with 1H HR-MAS spectroscopy of intact biopsy samples in vitro. Magma 8, 121-128.
90. Gupta RK, Sinha U, Cloughesy TF, and Alger JR (1999). Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 41, 2-7.
91. 1H MRS Data for the Assessment of Response to Therapy in Patients with Brain Tumors. Presented at Society of Magnetic Resonance, Third Scientific Meeting and Exhibition. Nice, France, 1960.
92. Nelson SJ, Huhn S, Vigneron DB, et al. (1997). Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 7, 1146-1152.
93. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, and Di Chiro G (1997). Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87, 516-524.
94. Wald LL, Nelson SJ, Day MR, et al. (1997). Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 87, 525-534.
95. Di Chiro G (1987). Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22, 360-371.
96. Nelson SJ, Day MR, Buffone PJ, Wald LL, Budinger TF, Hawkins R, Dillon WP, Huhn S, Prados MD, Chang S, and Vigneron DB (1997). Alignment of volume MR images and high resolution [18F] fluorodeoxyglucose PET images for the evaluation of patients with brain tumors. J Comput Assist Tomogr 21, 183-191.
97. Graves EE, Nelson SJ, Vigneron DB, et al. A preliminary study of the prognostic value of 1H-spectroscopy in Gamma Knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2/00.
98. Nelson SJ, Nalbandian AB, Proctor E, and Vigneron DB (1994). Registration of images from sequential MR studies of the brain. J Magn Reson Imaging 4, 877-883.
99. Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P, and Carroll PR (1994). Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 193, 703-709.
100. Ling D, Lee JK, Heiken JP, Balfe DM, Glazer HS, and McClennan BL (1986). Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases. Radiology 158, 103-107.
101. Rifkin M (1991). Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. Invest Radiol 26, 1024-1025.
102. Bartolozzi C, Menchi I, Lencioni R, Serni S, Lapini A, Barbanti G, Bozza A, Amorosi A, Manganelli A, and Carini M (1996). Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol 6, 339-345.
103. Choyke PL (1995). Imaging of prostate cancer. Abdom Imaging 20, 505-515.
104. Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, and Mitchell DG (1994). Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 193, 333-339.
105. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC, and McNeil BJ (1990). Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial [see comments]. N Engl J Med 323, 621-626.
106. Salo JO, Kivisaari L, Rannikko S, and Lehtonen T (1987). Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy. J Urol 137, 435-438.
107. Tempany CM, Zhou X, Zerhouni EA, Rifkin MD, Quint LE, Piccoli CW, Ellis JH, and McNeil BJ (1994). Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 192, 47-54.
108. Bates TS, Gillatt DA, Cavanagh PM, and Speakman M (1997). A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation. Br J Urol 79, 927-932.
109. Gerry DJ, Seltzer SE, Tempany CMC, Pickett RM, Swets JA, and McNeil BJ (1997). Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging. Radiology 204, 471-479.
110. Seltzer SE, Getty DJ, Tempany CMC, Pickett RM, Schnall MD, McNeil BJ, and Swets JA (1997). Staging of prostate cancer with MR imaging: a combined radiologist-computer system. Radiology 202, 219-226.
111. Yu KK, Hricak H, Alagappan R, Chernoff D, Bacchetti P, and Zaloudek C (1997). Detection of extracapsular extension of prostate carcinoma by endorectal/phased array coil MR imaging: multivariate analysis. Radiology 202, 697-702.
112. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek C, Nelson S, Carroll PR, and Kurhanewicz J (1999). Improved prediction of extracapsular extension in patients with prostate cancer by the addition of 3D H1-MR spectroscopic imaging to MR imaging. Submitted to Radiology 213, 481-488.
113. Vigneron DB, Nelson SJ, Moyher S, Kelley DAC, Kurhanewicz J, and Hricak H (1993). An Analytical Correction of MR Images obtained with Endorectal or Surface Coils. Presented at Society of Magnetic Resonance Imaging Eleventh Annual Meeting. San Francisco, CA. SMRI, 3(P), p. 142.
114. Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, and Zincke H (1997). Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 50, 733-739.
115. Presti JJ, Hovey R, Carroll PR, and Shinohara K (1996). Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. J Urol 156, 1685-1690.
116. Presti JJ, Hovey R, Bhargava V, Carroll PR, and Shinohara K (1997). Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations [see comments]. J Urol 157, 907-911; discussion 911-912.
117. Sommer FG, Nghiem HV, Herfkens R, McNeal J, and Low RN (1993). Determining the volume of prostate carcinoma: value of MR imaging with an external-array coil. AJR 161, 81-86.
118. White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, Weiss JM, Narayan P, and Carroll PR (1995). Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 195, 385-390.
119. Egawa S, Kawakami T, Nishimaki H, Kuwao S, Uchida T, Yokoyama E, Mashimo S, and Koshiba K (1994). Usefulness and limitation of digital rectal examination and imaging studies in staging prostate cancer. Nippon Hinyokika Gakkai Zasshi 85, 792-801.
120. Hricak H (1991). The prostate gland. In MRI of the Pelvis. H Hricak, BM Carrington (Eds). Dunitz, London, England. pp. 249-311.
121. Kalbhen CL, Hricak H, Chen M, Shinohara K, Parivar F, Kurhanewicz J, and Vigneron D (1996). Prostate carcinoma: MR imaging findings after cryosurgery. Radiology 198, 807-811.
122. Chen M, Hricak H, Kalbhen CL, Kurhanewicz J, Vigneron DB, Weiss JM, and Carroll PR (1996). Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol 166, 1157-1163.
123. Sommer FG, Nghiem HV, Herfkens R, and McNeal J (1993). Gadolinium-enhanced MRI of the abnormal prostate. Magn Reson Imaging 11, 941-948.
124. Namimoto T, Morishita S, Saitoh R, Kudoh J, Yamashita Y, and Takahashi M (1998). The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 22, 239-245.
125. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH, and Barentsz JO (1997). Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203, 645-652.
126. Turnbull LW, Buckley DL, Turnbull LS, Liney GP, and Knowles AJ (1999). Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 9, 311-316.
127. Bender H, Schomburg A, Albers P, Ruhlmann J, and Biersack HJ (1997). Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 17, 1655-1660.
128. Effert PJ, Bares R, Handt S, Wolff JM, Beull U, and Jakse G (1996). Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose [see comments]. J Urol 155, 994-998.
129. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, and Belldegrun A (1998). Positron emission tomography in urological oncology. J Urol 159, 347-356.
130. Shreve PD, Grossman HB, Gross MD, and Wahl RL (1996). Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199, 751-756.
131. Haseman MK, Reed NL, and Rosenthal SA (1996). Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 21, 704-713.
132. Hara T, Kosaka N, and Kishi H (1998). PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39, 990-995.
133. 18F]fluoropropyl)putrescine. Int J Rad Appl Instrum Part B 17, 525-532.
134. Fowler AH, Pappas AA, Holder JC, Finkbeiner AE, Dalrymple GV, Mullins MS, Sprigg JR, and Komoroski RA (1992). Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med 25, 140-147.
135. Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, and Heerschap A (1993). Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 150, 2019-2024.
136. Cornel EB, Smits GA, de Ruijter JE, Oosterhof GO, Heerschap A, Debruyne FM, and Schalken JA (1995). In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. Prostate 26, 275-280.
137. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, and Narayan P (1993). Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 29, 149-157.
138. Macdonald JM, Kurhanewicz J, Dahiya R, Espanol MT, Chang LH, Goldberg B, James TL, and Narayan P (1993). Effect of glucose and confluency on phosphorus metabolites of perfused human prostatic adenocarcinoma cells as determined by 31P MRS. Magn Reson Med 29, 244-248.
139. Yacoe ME, Sommer G, and Peehl D (1991). In vitro proton spectroscopy of normal and abnormal prostate. Magn Reson Med 19, 429-438.
140. Chelsky MJ, Schnall MD, Seidmon EJ, and Pollack HM (1993). Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 150 (2 Pt 1), 391-395.
141. Kier R, Wain S, and Troiano R (1993). Fast spin-echo MR images of the pelvis obtained with a phased-array coil: value in localizing and staging prostatic carcinoma. Ajr Am J Roentgenol 161, 601-606.
142. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, and Kressel HY (1989). Prostate: MR imaging with an endorectal surface coil. Radiology 172, 570-574.
143. 1H MR Spectroscopy of normal and malignant human porstates in vivo. J Magn Reson 87, 610-619.
144. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, and Lutz O (1993). Localized proton MR spectroscopy of citrate in vitro and of the prostate in vivo at 1.5 T. Magn Reson Med 29, 38-43.
145. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, and Horsman A (1997). In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 15, 1177-1186.
146. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, Ruijter ET, and Ruijs SH (1997). In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 17, 1455-1460.
147. Kim JK, Kim DY, Lee YH, Sung NK, Chung DS, Kim OD, and Kim KB (1998). In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. Magn Reson Imaging 16, 1281-1288.
148. Schiebler ML, Miyamoto KK, White M, Maygarden SJ, and Mohler JL (1993). In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 29, 285-291.
149. Cooper JF, and Farid I (1964). The role of citric acid in the physiology of the prostate: III. lactate/citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol 92, 533.
150. 13C NMR spectroscopy. Magn Reson Med 7, 384-411.
151. 1H nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumour tissues. Anal Commun 35, 113-115.
152. Costello LC, and Franklin RB (1991). Concepts of citrate production and secretion by prostate: 1. Metabolic relationships. Prostate 18, 25-46.
153. Kahn T, Burrig K, Schmitz DB, Lewin JS, Furst G, and Modder U (1989). Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology 173, 847-851.
154. Schiebler ML, Tomaszewski JE, Bezzi M, Pollack HU, Kressel HY, Cohen EK, Altman HG, Gefter WB, Wein AJ, and Axel L (1989). Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 172, 131-137.
155. Costello LC, and Franklin RB (1994). Bioenergetic theory of prostate malignancy. Prostate 25, 162-166.
156. Daly PF, Lyon RC, Faustino PJ, and Cohen JS (1987). Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 262, 14875-14878.
157. Daly PF, and Cohen JS (1989). Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res 49, 770-779.
158. Cohen JS (1988). Phospholipid and energy metabolism of cancer cells monitored by 31P magnetic resonance spectroscopy: possible clinical significance. Mayo Clin Proc 63, 1199-1207.
159. Cullis PR, and Hope MJ (1991). Physical Properties and Functional Roles of Lipids in Membranes. In: Biochemistry of Lipids, Lipoproteins and Membranes. DE Vance, J Vance (Eds). Elsevier Science Publishers, Amsterdam, pp. 1-41.
160. Mountford CE, and Wright LC (1988). Organization of lipids in the plasma membranes of malignant and stimulated cells: a new model. Trends Biochem Sci 13, 172-177.
161. Cheng LL, Wu CL, Smith MR, and Gonzalez RG (1999). Examining Human Prostate Specimens with HRMAS 1H MR Spectroscopy. Presented at Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine. Philadelphia, PA. 1, p. 114.
162. Cai H, Erhardt P, Troppmair J, Diaz-Meco MT, Sithanandam G, Rapp UR, Moscat J, and Cooper GM (1993). Hydrolysis of phosphatidylcholine couples Ras to
163. Cuadrado A, Carnera A, Dolfi F, Jimenez B, and Lacal JC (1993). Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 8, 2959-2968.
164. Exton JH (1994). Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1212, 26-42.
165. Pelech SL, and Vance DE (1989). Signal transduction via phosphatidylcholine cycles. Trends Biochem Sci 14, 28-30.
166. Agris PF, and Campbell ID (1982). Proton nuclear magnetic resonance of intact Friend leukemia cells: phosphorylcholine increase during differentiation. Science 216, 1325-1327.
167. Carpinelli G, Podo F, Di VM, Proietti E, Gessani S, and Belardelli F (1984). Modulations of glycerophosphorylcholine and phosphorylcholine in Friend erythroleukemia cells upon in vitro-induced erythroid differentiation: a 31P NMR study. FEBS Lett 176, 88-92.
168. Galons JP, Fantini J, Vion DJ, Cozzone PJ, and Canioni P (1989). Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy. Biochimie 71, 949-961.
169. Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, and Carroll PR (1996). Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200, 489-496.
170. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, and Ruijs SH (1997). Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 37, 204-213.
171. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, and Carroll PR (1996). Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48, 594-599.
172. Parivar F, and Kurhanewicz J (1998). Detection of recurrent prostate cancer after cryosurgery. Curr Opin Urol 8, 83-86.
173. McNeal J (1983). The prostate gland: morphology and pathobiology. Monogr Urol 4, 3-33.
174. Stamey TA, McNeal JE, Freiha FS, and Redwine E (1988). Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139, 1235-1241.
175. Gleason D (1992). Histologic grading of prostate cancer: a perspective. Hum Pathol 23, 273-279.
176. Costello LC, Littleton GK, and Franklin RB (1978). Regulation of citrate-related metabolism in normal and neoplastic prostate. In: Endocrine Control in Neoplasia. RK Sharma, WE Criss (Eds). Raven Press, New York. pp. 303-314.
177. Marberger H, Marberger E, Mann T, and Lutwak-Mann C (1962). Citric acid in human prostatic secretion and metastasizing cancer of prostate gland. Br Med J 1, 835-836.
178. Vigneron D, Males R, Hricak H, Noworolski S, Carrol PR, and Kurhanewicz J (1998). Prostate Cancer: Correlation of 3D MRSI Metabolite Levels with Histologic Grade. Presented at RSNA. Chicago, IL. 209(P), p. 181.
179. Dueck DA, Chan M, Tran K, Wong JT, Jay FT, Littman C, Stimpson R, and Choy PC (1996). The modulation of choline phosphoglyceride metabolism in human colon cancer. Mol Cell Biochem 162, 97-103.
180. Katz-Brull R, and Degani H (1996). Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16, 1375-1380.
181. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, Mitsui I, Kosaka N, Kondo T, and Hara T (1997). Brain tumors: detection with C-11 choline PET. Radiology 202, 497-503.
182. Tsujiuchi T, Kido A, Nakae D, Takahama M, Majima T, Kobitsu K, Okajima E, Tsutsumi M, Denda A, and Konishi Y (1996). Infrequent Ki-ras and an absence of p53 mutations in hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Lett 108, 137-141.
183. Zeisel SH, da Costa KA, Albright CD, and Shin OH (1995). Choline and hepatocarcinogenesis in the rat. Adv Exp Med Biol 375, 65-74.
184. Lacal JC, Moscat J, and Aaronson SA (1987). Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 330, 269-272.
185. Macara IG (1989). Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 9, 325-328.
186. Jimenez B, del Peso L, Montaner S, Esteve P, and Lacal JC (1995). Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 57, 141-149.
187. Carnero A, Cuadrado A, del Peso L, and Lacal JC (1994). Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. Oncogene 9, 1387-1395.
188. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, Espinosa A, and Lacal JC (1997). Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15, 2289-2301.
189. Ratnam S, and Kent C (1995). Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 323, 313-322.
190. Teegarden D, Taparowsky EJ, and Kent C (1990). Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J Biol Chem 265, 6042-6047.
191. 1H-MR spectroscopic imaging in localizing prostate cancer: clinico-pathologic study. Radiology 213, 473-480.
192. Kaji Y, Kurhanewicz J, Hricak H, Sokolov D, Huang LR, Nelson S, and Vigneron D (1998). Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206, 785-790.
193. Bostwick DG, Graham SD, Jr., Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, et al. (1993). Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology 41, 403-411.
194. Bostwick DG, Egbert BM, and Fajardo LF (1982). Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 6, 541-551.
195. Ronnett BM, Carmichael MJ, Carter HB, and Epstein JI (1993). Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? [see comments]. J Urol 150, 386-389.
196. Chen C-N, and Hoult DI (1989). Biomedical Magnetic Resonance Technology. In Medical Science Series. RF Mould (Ed). Adam Hilger, Bristol and New York.
197. Bessette A, Mueller-Lisse UG, Swanson M, Vigneron DV, Scheidler J, Srivastava A, Wood P, Hricak H, Carroll P, Nelson SJ, and Kurhanewicz J (1999). Localization of Prostate Cancer After Hormone Ablation by MRI and 3D 1H MRSI: Case-Control Study with Pathologic Correlation. Presented at Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine. Philadelphia, PA. 3, p. 1519.
198. Mueller-Lisse UG, Kurhanewicz J, Bessette A, Males R, Swanson M, Fang A, Nelson S, Hricak H, Barken I, and Vigneron DB (1999). Hormone Ablation of Localized Prostate Cancer: Effects of Duration of Therapy on Prostate Metabolism Demonstrated by 3D 1H MR Spectroscopy. Presented at Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine. Philadelphia, PA. 3, p. 1518.
199. Males R, Okuno W, Vigneron DB, Swanson M, Wood P, Nelson SJ, Roach M, and Kurhanewicz J (1999). Monitoring Effects of Prostate Cancer Brachytherapy Using Combined MRI/MRS. Presented at Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine. Philadelphia, PA. 1, p. 115.
200. Scharen-Guivek VLM, Males R, Nelson SJ, Mueller-Lisse UG, Vigneron DB, and Kurhanewicz J (1999). Evaluation of Local Prostate Recurrence After Radical Prostectomy Using Magnetic Resonance Spectrosscopic Imaging. Presented at Seventh Annual Meeting of the International Society for Magnetic Resonance In Medicine. Philadelphia, PA. 1, p. 117.